Mohammad-Reza Zarrindast Selected Research

harman (harmane)

9/2019	The effect of CA1 dopaminergic system on amnesia induced by harmane in mice.
1/2019	Correction to: The effect of CA1 dopaminergic system on amnesia induced by harmane in mice.
1/2019	Abolishment of fear memory-disruptive effects REM sleep deprivation by harmane.
12/2016	Additive effect of harmane and muscimol for memory consolidation impairment in inhibitory avoidance task.
11/2013	Suggesting a possible role of CA1 histaminergic system in harmane-induced amnesia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohammad-Reza Zarrindast Research Topics

Disease

57	Amnesia (Dissociative Amnesia) 06/2021 - 08/2004
16	Memory Disorders (Memory Loss) 12/2021 - 03/2014
14	Pain (Aches) 10/2022 - 01/2006
13	Sleep Deprivation 02/2022 - 01/2016
7	Substance-Related Disorders (Drug Abuse) 10/2020 - 01/2014
6	Opioid-Related Disorders (Opiate Addiction) 07/2015 - 07/2009
5	Alzheimer Disease (Alzheimer's Disease) 05/2022 - 04/2014
5	Cognitive Dysfunction 04/2022 - 11/2013
5	Cholestasis 01/2020 - 06/2013
4	Mental Disorders (Mental Disorder) 01/2022 - 01/2019
4	Morphine Dependence 01/2022 - 09/2002
4	Hypothermia 01/2020 - 09/2002
3	Nervous System Diseases (Neurological Disorders) 04/2022 - 01/2019
3	Mood Disorders (Mood Disorder) 01/2022 - 09/2015
3	Parkinson Disease (Parkinson's Disease) 12/2021 - 01/2012
2	Stroke (Strokes) 04/2022 - 01/2020
2	Multiple Sclerosis 04/2022 - 02/2020
2	Anxiety Disorders (Anxiety Disorder) 01/2022 - 01/2009
2	Inflammation (Inflammations) 01/2022 - 12/2020
2	Neuralgia (Stump Neuralgia) 01/2021 - 12/2018
2	Hepatic Encephalopathy 12/2020 - 10/2016
2	B-Cell Lymphoma (Lymphoma, B Cell) 12/2020 - 01/2020
2	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2020 - 10/2018
2	Neoplasms (Cancer) 07/2020 - 08/2013
2	Hyperalgesia 01/2019 - 05/2003

Drug/Important Bio-Agent (IBA)

37	Morphine (MS Contin)FDA LinkGeneric 01/2022 - 05/2002
14	Pharmaceutical PreparationsIBA 01/2021 - 05/2003
13	Opioid Analgesics (Opioids)IBA 01/2022 - 05/2002
13	Sulpiride (neogama)IBA 12/2021 - 08/2004
12	Naloxone (Narcan)FDA LinkGeneric 01/2020 - 05/2002
11	SCH 23390IBA 09/2019 - 08/2004
8	CannabinoidsIBA 10/2022 - 01/2015
8	Nicotine FDA Link 01/2019 - 05/2002
7	Dopamine (Intropin)FDA LinkGeneric 04/2022 - 09/2002
7	MuscimolIBA 01/2020 - 01/2006
6	Anti-Anxiety Agents (Anxiolytics)IBA 12/2021 - 08/2013
6	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2017 - 05/2010
6	N-Methylaspartate (NMDA)IBA 10/2016 - 12/2008
6	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2016 - 03/2013
5	Therapeutic UsesIBA 04/2022 - 02/2020
5	RS 67333IBA 06/2021 - 03/2014
5	harman (harmane)IBA 09/2019 - 11/2013
5	Messenger RNA (mRNA)IBA 01/2018 - 07/2009
5	Glutamic Acid (Glutamate)FDA Link 01/2017 - 06/2006
5	LithiumIBA 10/2016 - 11/2006
4	AntioxidantsIBA 01/2022 - 01/2020
4	Arginine (L-Arginine)FDA Link 12/2021 - 06/2006
4	NG-Nitroarginine Methyl Ester (L-NAME)IBA 12/2021 - 06/2006
4	Scopolamine (Hyoscine)FDA Link 10/2020 - 05/2010
4	NeuroaidIBA 06/2020 - 01/2019
4	Clonidine (ST 155)FDA LinkGeneric 01/2020 - 07/2003
4	2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)IBA 09/2019 - 08/2004
4	Dopamine Receptors (Dopamine Receptor)IBA 01/2019 - 08/2005
4	BicucullineIBA 01/2017 - 01/2006
4	mu Opioid Receptors (mu Opioid Receptor)IBA 04/2014 - 07/2009
3	Tramadol (K315)FDA LinkGeneric 01/2022 - 01/2019
3	Analgesics (Analgesic Drugs)IBA 01/2022 - 01/2018
3	QuinpiroleIBA 12/2021 - 08/2004
3	salicylhydroxamic acid (SHAM)IBA 03/2021 - 06/2013
3	Neuroprotective AgentsIBA 01/2021 - 12/2018
3	AM 251 (AM251)IBA 01/2021 - 03/2013
3	Imipramine (Janimine)FDA LinkGeneric 01/2021 - 07/2003
3	5-HT4 Serotonin ReceptorsIBA 01/2020 - 03/2014
3	Yohimbine (Yocon)IBA 01/2020 - 07/2003
3	Ketamine FDA LinkGeneric 11/2019 - 06/2016
3	Neurotransmitter Agents (Neurotransmitter)IBA 04/2019 - 09/2015
3	Streptozocin (Streptozotocin)FDA Link 01/2019 - 11/2013
3	Dopamine AntagonistsIBA 01/2019 - 08/2013
3	azasetronIBA 09/2017 - 03/2014
3	Dizocilpine Maleate (Dizocilpine)IBA 04/2016 - 06/2006
3	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2016 - 07/2003
3	Ethanol (Ethyl Alcohol)IBA 03/2013 - 12/2008
3	MecamylamineIBA 07/2008 - 05/2002
2	EndocannabinoidsIBA 10/2022 - 01/2006
2	HarmalineIBA 10/2022 - 10/2014
2	Thimerosal (Thiomersal)IBA 06/2022 - 05/2018
2	Serotonin (5 Hydroxytryptamine)IBA 02/2022 - 11/2013
2	Antidepressive Agents (Antidepressants)IBA 01/2022 - 12/2021
2	Oxidopamine (6 Hydroxydopamine)IBA 12/2021 - 12/2021
2	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 12/2021 - 11/2019
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2021 - 06/2006
2	Cytidine Diphosphate Choline (Citicoline)IBA 01/2021 - 10/2018
2	Amyloid (Amyloid Fibrils)IBA 12/2020 - 01/2019
2	NeuropeptidesIBA 06/2020 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2018
2	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 01/2018
2	Malondialdehyde (Propanedial)IBA 01/2020 - 11/2013
2	gamma-Aminobutyric Acid (GABA)IBA 01/2020 - 01/2017
2	Adenosine Triphosphate (ATP)IBA 01/2020 - 12/2006
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2020 - 04/2008
2	Dopamine Agents (Dopaminergic Agents)IBA 09/2019 - 06/2016
2	Cholinergic Agents (Cholinergics)IBA 10/2017 - 01/2006
2	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 10/2017 - 04/2014
2	PhysostigmineIBA 10/2017 - 01/2006

Therapy/Procedure

11	Injections 09/2019 - 08/2004
4	Therapeutics 07/2020 - 07/2009
4	Analgesia 01/2019 - 09/2017
4	Ligation 10/2016 - 06/2013
3	Transcranial Direct Current Stimulation 01/2019 - 11/2017
2	Cognitive Training 04/2022 - 01/2020